NCT00084045

Brief Summary

Voluntary HIV counseling and testing (VCT) and anti-HIV drugs for pregnant women and their newborns decrease rates of mother-to-child transmission (MTCT) of HIV. This study will determine the acceptability of HIV counseling and rapid testing prior to delivery and will compare the usefulness of VCT prior to birth versus after birth in preventing MTCT of HIV in pregnant women in Cape Town, South Africa. This study will also determine the acceptability and effectiveness of giving anti-HIV medications to prevent MTCT of HIV.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
283

participants targeted

Target at P50-P75 for not_applicable hiv-infections

Timeline
Completed

Started Nov 2004

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 4, 2004

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 7, 2004

Completed
5 months until next milestone

Study Start

First participant enrolled

November 1, 2004

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
Last Updated

October 30, 2012

Status Verified

October 1, 2012

First QC Date

June 4, 2004

Last Update Submit

October 26, 2012

Conditions

Keywords

HIV SeronegativityTreatment NaivePediatric HIVPerinatal Transmission

Outcome Measures

Primary Outcomes (10)

  • Time required to obtain informed consent

  • time from initiation of HIV pre-test counseling until test results are available

  • proportion of test evaluations completed before delivery

  • proportion of test evaluations completed before hospital discharge

  • proportion of women who agree to HIV testing

  • proportion of women identified as HIV infected during labor who accept ARV prophylaxis

  • proportion of women identified as HIV infected after birth who accept ARV therapy for their infants

  • timing of infant ARV prophylaxis initiation after birth, as a proportion of infants born to women identified as HIV infected after birth and as a continuous variable

  • timing of mother ARV initiation as a proportion of women identified as HIV infected during labor and as a continuous variable

  • qualitative measures (defined as available space, study staff allocation, support for counseling and testing, and women's perceptions and opinions of counseling and testing)

Secondary Outcomes (6)

  • Proportion of women with undocumented HIV infection who are tested and determined to be HIV infected peripartum

  • performance of rapid HIV tests as measured by sensitivity and specificity

  • proportion of infants who complete the Week 6 study visit and efforts needed to accomplish this visit

  • proportion of infants being fed according to the method chosen at discharge (defined as exclusive breastfeeding, exclusive formula feeding, or mixed feeding), as reported by the mother at Week 6

  • proportion of HIV-exposed infants who acquire HIV infection during delivery and after birth

  • +1 more secondary outcomes

Interventions

Eligibility Criteria

Age14 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Unknown HIV infection status
  • At least seven months pregnant
  • Women in active labor who have planned induction or Caesarean delivery or any other condition requiring planned delivery
  • Mother is participating in study
  • Mother is HIV infected

You may not qualify if:

  • Women in labor who need immediate delivery
  • Obstetrical emergencies in which the woman is medically unstable or requires emergency delivery
  • Diagnosed fetal death or fetal condition requiring abortion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hottentots Holland Hospital

Cape Town, 7505, South Africa

Location

Maccassar Community Health Clinic

Cape Town, 7505, South Africa

Location

Related Publications (5)

  • Leroy V, Sakarovitch C, Cortina-Borja M, McIntyre J, Coovadia H, Dabis F, Newell ML, Saba J, Gray G, Ndugwa Ch, Kilewo Ch, Massawe A, Kituuka P, Okong P, Grulich A, von Briesen H, Goudsmit J, Biberfeld G, Haverkamp G, Weverling GJ, Lange JM; Ghent Group on HIV in Women and Children. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS. 2005 Nov 4;19(16):1865-75. doi: 10.1097/01.aids.0000188423.02786.55.

    PMID: 16227795BACKGROUND
  • McIntyre J. Strategies to prevent mother-to-child transmission of HIV. Curr Opin Infect Dis. 2006 Feb;19(1):33-8. doi: 10.1097/01.qco.0000200290.99790.72.

    PMID: 16374215BACKGROUND
  • Newell ML. Current issues in the prevention of mother-to-child transmission of HIV-1 infection. Trans R Soc Trop Med Hyg. 2006 Jan;100(1):1-5. doi: 10.1016/j.trstmh.2005.05.012. Epub 2005 Oct 7.

    PMID: 16214193BACKGROUND
  • Bulterys M, Jamieson DJ, O'Sullivan MJ, Cohen MH, Maupin R, Nesheim S, Webber MP, Van Dyke R, Wiener J, Branson BM; Mother-Infant Rapid Intervention At Delivery (MIRIAD) Study Group. Rapid HIV-1 testing during labor: a multicenter study. JAMA. 2004 Jul 14;292(2):219-23. doi: 10.1001/jama.292.2.219.

  • Jamieson DJ, O'Sullivan MJ, Maupin R, Cohen M, Webber MP, Nesheim S, Lampe M, Garcia P, Lindsay M, Bulterys M. The challenges of informed consent for rapid HIV testing in labor. J Womens Health (Larchmt). 2003 Nov;12(9):889-95. doi: 10.1089/154099903770948113.

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Robert Maupin, Jr., MD

    Louisiana State University Health Science Center

    STUDY CHAIR
  • Mitchell Besser, MD

    Department of Obstetrics and Gynecology, Groote Schuur Hospital Observatory

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2004

First Posted

June 7, 2004

Study Start

November 1, 2004

Study Completion

December 1, 2006

Last Updated

October 30, 2012

Record last verified: 2012-10

Locations